Whole exome sequencing (WES) of methotrexate response/adverse event profile in rheumatoid arthritis patients

Goulielmos, 2016, Genetic data: the new challenge of personalized medicine, insights for rheumatoid arthritis patients, Gene, 583, 90, 10.1016/j.gene.2016.02.004 Chatzidionysiou, 2019, Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift, RMD Open, 5, 10.1136/rmdopen-2019-000993 Curtis, 2016, Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review, J Rheumatol, 43, 1997, 10.3899/jrheum.151212 Kłak, 2016, Personalized medicine in rheumatology, Reumatologia, 54, 177, 10.5114/reum.2016.62472 Bedoui, 2019, Methotrexate an old drug with new tricks, Int J Mol Sci, 20, 5023, 10.3390/ijms20205023 Gremese, 2019, JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy, J Leukoc Biol, 106, 1063, 10.1002/JLB.5RU0519-145R Conway, 2017, Risk of liver disease in methotrexate treated patients, World J Hepatol, 9, 1092, 10.4254/wjh.v9.i26.1092 Bello, 2017, Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis, Open Access Rheumatol, 9, 67, 10.2147/OARRR.S131668 Vena, 2018, Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis, Ther Clin Risk Manag, 14, 105, 10.2147/TCRM.S154745 Qiu, 2017, Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic review and meta-analysis, Medicine (Baltimore), 96, 10.1097/MD.0000000000006337 Taylor, 2019, How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?-MTX in the treat-to-target strategy, J Clin Med, 8, 10.3390/jcm8040515 Taylor, 2018, Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients, Pharmacogenom J, 18, 528, 10.1038/s41397-018-0025-5 Qiu, 2017, Polymorphisms and pharmacogenomics for the clinical efficacy of methotrexate in patients with rheumatoid arthritis: a systematic review and meta-analysis, Sci Rep, 7, 44015, 10.1038/srep44015 Furukawa, 2015, Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis, J Hum Genet, 60, 691, 10.1038/jhg.2015.36 Sacristán, 2019, Treat-to-target and treat-to-budget in rheumatoid arthritis: measuring the value of individual therapeutic interventions, Rheumatol Ther, 6, 473, 10.1007/s40744-019-00178-3 Batko, 2019, Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis, J Clin Med, 8, 10.3390/jcm8091416 van Vollenhoven, 2019, Treat-to-target in rheumatoid arthritis – are we there yet?, Nat Rev Rheumatol, 15, 180, 10.1038/s41584-019-0170-5 Lima, 2016, Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome, Pharmacogenomics, 17, 1649, 10.2217/pgs-2016-0067 Aletaha, 2010, Bingham CO 3rd, et al 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism Collaborative Initiative, Arthritis Rheum, 62, 2569, 10.1002/art.27584 Felson, 1993, The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials, Arthritis Rheum, 36, 729, 10.1002/art.1780360601 Wishart, 2018, Drug Bank 5.0: a major update to the Drug Bank database for 2018, Nucl Acids Res, 46, D1074, 10.1093/nar/gkx1037 Gheita, 2019, Rheumatology in Egypt: back to the future, Rheumatol Int, 39, 1, 10.1007/s00296-018-4192-0 Hegab, 2016, CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians, Hum Immunol, 77, 522, 10.1016/j.humimm.2016.04.018 Januchowski, 2013, Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines, Biomed Pharmacother, 67, 240, 10.1016/j.biopha.2012.11.011 Haas, 2015, Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions, PLoS Biol, 13, 10.1371/journal.pbio.1002202 Jansen, 2003, Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview, Scand J Rheumatol, 32, 325, 10.1080/03009740310004333 Márki-Zay, 2013, MDR-ABC transporters: biomarkers in rheumatoid arthritis, Clin Exp Rheumatol, 31, 779 Shibayama, 2006, Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats, Cancer Sci, 97, 1260, 10.1111/j.1349-7006.2006.00304.x Ranganathan, 2013, ABC transporter genes and methotrexate response in rheumatoid arthritis, J Rheumatol, 40, 536, 10.3899/jrheum.121361 Boilard, 2010, Platelets amplify inflammation in arthritis via collagen-dependent microparticle production, Science, 327, 580, 10.1126/science.1181928 Wang, 2009, Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus, BMC Musculoskelet Disord, 10, 141, 10.1186/1471-2474-10-141 Steinbusch, 2017, Serum snoRNAs as biomarkers for joint ageing and post traumatic osteoarthritis, Sci Rep, 7, 43558, 10.1038/srep43558 Ohbayashi, 2013, Differential mRNA expression and the uptake of methotrexate in primary MAEC and MLF cells: involvement of the Abc and Slco/Oatp transporters in alveolar epithelial cell toxicity, J Toxicol Sci, 38, 103, 10.2131/jts.38.103 Torices, 2016, A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis, Arthritis Res Ther, 18, 221, 10.1186/s13075-016-1113-z Yang, 2010, Dynamic cross-talk analysis among TNF-R, TLR-4 and IL-1R signalings in TNFα-induced inflammatory responses, BMC Med Genom, 3, 19, 10.1186/1755-8794-3-19 Friedman, 2019, Methotrexate mechanism in treatment of rheumatoid arthritis, Joint Bone Spine, 86, 301, 10.1016/j.jbspin.2018.07.004 Lee, 2016, Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis, Rheumatol Int, 36, 1591, 10.1007/s00296-016-3523-2 Lima, 2014, Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms, Biomed Res Int, 2014, 10.1155/2014/368681 Kurzawski, 2016, ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients, Pharmacogenomics, 17, 1971, 10.2217/pgs-2016-0125 Chen, 2019, Folate receptor-targeting and reactive oxygen species-responsive liposomal formulation of methotrexate for treatment of rheumatoid arthritis, Pharmaceutics, 11, pii: E582, 10.3390/pharmaceutics11110582